Fine-Tuning Therapeutic Strategies in Acute Myeloid Leukemia
prIME Downloadable Slides
prIME Downloadable Slides

Fine-Tuning Therapeutic Strategies in Acute Myeloid Leukemia

View Activities

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.

Expand your understanding of AML targeted therapy options and how cytogenetics influences treatment decisions with these downloadable slides. Initial discussion will focus on AML subgroups classification. From there, options in initial therapy and relapsed or refractory disease will be featured. Finally, new targeted options will be examined in detail.

Downloadable Slides

Downloadable Slides

IME

IME

Release Date

Release Date

Jun 22, 2017

Expiration Date

Jun 22, 2018

Featured Expert

  • Elli Papaemmanuil, PhD, Memorial Sloan Kettering Cancer Center, New York, New York, United States

Featured Topic

Examining genetics and genomics in AML in 2017

Featured Expert

  • Francesco Lo Coco, MD, University Tor Vergata, Rome, Italy

Featured Topic

Personalizing initial therapy in AML

Featured Expert

  • Lisa Pleyer, MD, Salzburg Cancer Research Institute, Salzburg, Austria

Featured Topic

What’s on the horizon for relapsed/refractory AML?

Featured Expert

  • Miguel Sanz, MD, Valencia University Medical School, University Hospital La Fe, Valencia, Spain

Featured Topic

A deeper dive into AML subgroups

This activity is specifically designed to meet the needs of medical, surgical, and radiation oncologists, hematologists, and other healthcare professionals involved in the treatment of patients with cancer.

After successful completion of this educational activity, participants should be able to:

  • Compare current AML classification systems and the role that cytogenetics plays in them
  • Evaluate current initial therapeutic strategies in newly-diagnosed AML based on patient and disease characteristics
  • Identify novel agents being investigated in relapsed/refractory AML
  • Describe molecularly-defined subtypes of AML

This educational activity is supported by grants from Celgene, Helsinn Healthcare SA, and Novartis Oncology.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.